Pharmadrug Inc. Share Price OTC Markets
Stocks
LMLLF
CA71716W2040
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
14:30:03 12/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.003500 USD | -37.05% |
|
-59.30% | -60.67% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-30 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.34M 964K 835K 783K 714K 91.96M 1.36M 9.21M 3.6M 46.05M 3.62M 3.54M 154M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.84M 2.04M 1.77M 1.66M 1.51M 195M 2.89M 19.5M 7.62M 97.54M 7.67M 7.5M 325M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -37.05% | ||
| 1 week | -59.30% | ||
| Current month | -44.44% | ||
| 1 month | -36.13% | ||
| 3 months | -60.23% | ||
| 6 months | -52.05% | ||
| Current year | -60.67% |
| 1 week | 0 |  | 0.01 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.06 |
| 5 years | 0 | | 0.49 |
| 10 years | 0 | | 2.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 19/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 19/12/2016 |
David Kideckel
CHM | Chairman | - | 26/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -37.05% | -59.30% | - | - | 963K | |
| -2.55% | +0.17% | +33.34% | +99.68% | 105B | |
| -2.54% | -2.12% | +60.05% | +153.47% | 55.88B | |
| +0.17% | -0.84% | +3.67% | +268.32% | 24.12B | |
| -0.78% | +0.61% | -12.93% | -14.11% | 8.28B | |
| -1.04% | +5.66% | -30.42% | -25.18% | 7.75B | |
| -0.18% | -2.57% | -13.81% | -21.97% | 6.69B | |
| +0.48% | +0.43% | +18.27% | +16.29% | 6.16B | |
| -1.41% | -4.96% | -5.85% | +19.81% | 5.01B | |
| -0.59% | +2.65% | -5.97% | -4.99% | 3.75B | |
| Average | -4.58% | +0.29% | +5.15% | +54.59% | 24.75B | |
| Weighted average by Cap. | -1.93% | -0.28% | +29.52% | +113.34% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -570K -494K -463K -422K -54.35M -805K -5.44M -2.13M -27.22M -2.14M -2.09M -90.75M | -383K -275K -239K -224K -204K -26.27M -389K -2.63M -1.03M -13.15M -1.03M -1.01M -43.86M |
| Net Debt | 1.27M 915K 793K 743K 678K 87.29M 1.29M 8.74M 3.42M 43.71M 3.44M 3.36M 146M | 1.5M 1.08M 934K 875K 798K 103M 1.52M 10.29M 4.02M 51.49M 4.05M 3.96M 172M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/08/26 | US$0.003500 | -37.05% | 500 |
| 11/08/26 | US$0.005560 | -19.42% | 9,420 |
| 07/08/26 | US$0.006900 | +36.36% | 5,000 |
| 06/08/26 | US$0.005060 | -41.16% | 140,046 |
| 05/08/26 | US$0.008600 | +16.22% | 5,000 |
- Stock Market
- Stocks
- PHRX Stock
- LMLLF Stock
Select your edition
All financial news and data tailored to specific country editions
